Keyhole-limpet haemacyanin and immune ribonucleic acid immunotherapy of murine transitional cell carcinoma.
Transitional cell carcinoma is known to be an immunogenic tumour. This immunogenicity has been the basis of a search for effective immunotherapeutic agents and for the evaluation in this study of two additional agents, keyhole-limpet haemacyanin (KLH) and immune ribonucleic acid (RNA) extract. The results in this animal model showed KLH to be a potent non-specific stimulant of the immune response which caused both a reduction in tumour growth and a prolongation of animal survival (p = 0.01). No anti-tumour effects were observed with either local or systemic RNA.
D000818:Animals; D000941:Antigens / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000628:therapy*; D006433:Hemocyanins; D006801:Humans; D007114:Immunization; D007167:Immunotherapy; D008198:Lymph Nodes / Q000276:immunology; D051379:Mice; D008809:Mice, Inbred C3H; D009374:Neoplasms, Experimental; D012334:RNA, Neoplasm / Q000302:isolation & purification / Q000627:therapeutic use*; D013154:Spleen / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
D000941:Antigens; D012334:RNA, Neoplasm; D006433:Hemocyanins; C032808:keyhole-limpet hemocyanin